Skip to content

Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer

Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03235648
Enrollment
25
Registered
2017-08-01
Start date
2017-06-01
Completion date
2023-06-01
Last updated
2017-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer

Brief summary

Evaluation of surgical excision of cardiophrenic lymph nodes in patients with advanced ovarian cancer

Detailed description

The role of cardiophrenic lymph node assessment and excision in advanced ovarian cancer is still debatable , correlation of radiological finding with pathological findings after reaction of radiological positive lymph nodes and its impact in diseases free survival and over all survival

Interventions

PROCEDUREcardiophrenic lymph nodes resection

surgical resection

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Ovarian cancer patient (FIGO stage III-IV) * Preoperative CT showing CPLN with short axis diameter \> 5mm. * Anathestically fit patient (ASA score I or II). * Accepted pulmonary function test. * Patient who received neoadjuvant chemotherapy or recurrent cases may be enrolled * Written informed consent. * Achievement of optimal cytoreduction intra-abdominal( No residual disease more than 1 cm )

Exclusion criteria

* Anathestically unfit patient * Unresectable disease * Patient refusal * No detected CPLN by preoperative radiology

Design outcomes

Primary

MeasureTime frameDescription
number of CPN retrieved/pathological nodesup to 3 yearscorrelation of radiological active lymph nodes with pathological findings

Secondary

MeasureTime frameDescription
Progression free survivalup to 2 years following the end of study2 years progression without disease recurrence

Other

MeasureTime frameDescription
Overall survivalup to 2 years following the end of study2 years survivals of the patients

Countries

Egypt

Contacts

Primary ContactBasel R. Abdelfattah, MD, MRCS
dr.basel@hotmail.com01001974340

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026